Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

ivf hartmann ag - benzalkonii chloridum, alcol isopropylicus - soluzione - benzalkonii chloridum 0.22 mg, alcohol isopropylicus 553 mg, e 104, e 110, e 151, aqua purificata, ad solutionem pro 1 ml. - hautdesinfiziens - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

ivf hartmann ag - benzalkonii chloridum, alcol isopropylicus - soluzione - benzalkonii chloridum 0.22 mg, alcohol isopropylicus 552 mg, aqua purificata, ad solutionem pro 1 ml. - hautdesinfiziens - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

gebro pharma ag - natrii chloridum, kalii chloridum, natrii citras dihydricus, glucosum - pulver zur herstellung einer lösung zum einnehmen im beutel - natrii chloridum 0.35 g, kalii chloridum 0.30 g, natrii citras dihydricus 0.59 g, glucosum 4.00 g, saccharinum natricum, aromatica golden syrup, aromatica tutti frutti cum alcohol benzylicus et propylenglycolum, silica colloidalis anhydrica, ad pulverem, pro charta corresp. natrium 276 mg, kalium 157 mg. - elettroliti per la reidratazione orale - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - ethanolum 96 per cento, alcol isopropylicus - soluzione - ethanolum 96 per centum 654.3 mg, alcohol isopropylicus 83 mg, aqua purificata q.s. ad solutionem pro 1 ml. - hautdesinfiziens - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - ethanolum 96 per cento, alcol isopropylicus - soluzione - ethanolum 96 per centum 654.3 mg, alcohol isopropylicus 83 mg, povidonum k 30, acidum citricum monohydricum, e 110, e 122, aqua purificata, q.s. ad solutionem pro 1 ml. - hautdesinfiziens - synthetika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

organogenesis switzerland gmbh - umana cheratinociti, fibroblasti umani - apligraf - human keratinocytes 33 %, human fibroblasts 67%, collagena, dulbecco's modified eagle medium, ham's f12, natrii hydrogenocarbonas, calcii chloridum dihydricum, glutaminum, adeninum, acidum selenicum, ethanolaminum, phosphatidylethanolaminum, hydrocortisonum, insulinum humanum (emp) (rekombinates human insulinanalogon), aqua ad iniectabile, pro praeparatione. - apligraf ist indiziert bei erwachsenen patienten für die behandlung von diabetischen fussulzera neuropathischer Ätiologie; apligraf ist indiziert bei erwachsenen patienten für die behandlung von chronischen, nicht-infizierten venösen beinulzera (iaet stadium ii oder iii), welche durch venöse insuffizienz verursacht werden - trapianto: gewebeprodukt

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ustekinumabum - soluzione iniettabile - ustekinumabum 45 mg, saccharum, histidinum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - plaque-psoriasis ab 6 jahren, psoriasis-arthritis bei erwachsenen, morbus crohn bei erwachsenen, ulcerative colitis bei erwachsenen - biotechnologika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 6a conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 6b conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 7f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 9v conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 18c conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 19a conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 19f conjugata cum proteino corynebacteriae diphtheriae crm 197, polysaccharida streptococci pneumoniae typus 23f conjugata cum proteino corynebacteriae diphtheriae crm 197 - sospensione iniettabile in una siringa preriempita - polysaccharida streptococci pneumoniae typus 1 conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 3 conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 4 conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 5 conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 6a conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 6b conjugata cum proteino corynebacteriae diphtheriae crm 197 4.4 µg et polysaccharida streptococci pneumoniae typus 7f conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 9v conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 14 conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 18c conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 19a conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 19f conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg et polysaccharida streptococci pneumoniae typus 23f conjugata cum proteino corynebacteriae diphtheriae crm 197 2.2 µg corresp. polysaccharida 30.8 µg et proteinum corynebacteriae diphtheriae crm 197 ca. 32 µg, adjuvans: aluminium ut aluminii phosphas, natrii chloridum corresp. natrium 1.67 mg, acidum succinicum, polysorbatum 80, aqua ad iniectabile q.s. ad suspensionem pro 0.5 ml. - aktive immunisierung gegen pneumokokken-infektionen der serotypen 1, 3, 4, 5, 6a, 6b, 7f, 9v, 14, 18c, 19a, 19f, 23f - vaccini

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ustekinumabum - soluzione iniettabile in siringa preriempita - ustekinumabum 45 mg, saccharum, histidinum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 0.5 ml. - plaque-psoriasis ab 6 jahren, psoriasis-arthritis, morbus crohn, ulcerative colitis - biotechnologika

Schweiz - italienska - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - ustekinumabum - soluzione iniettabile in siringa preriempita - ustekinumabum 90 mg, saccharum, histidinum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis ab 6 jahren, psoriasis-arthritis, morbus crohn, ulcerative colitis - biotechnologika